Sanofi's Duty To Detail FDA Concerns Key To Lemtrada Cases
A New York federal judge asked Friday whether Sanofi's "very happy opinion" shared with investors about prospects for on-time approval of its potential blockbuster Lemtrada multiple sclerosis drug carried with it...To view the full article, register now.
Already a subscriber? Click here to view full article